Literature DB >> 10728879

Dopamine transporter synthesis and degradation rate in rat striatum and nucleus accumbens using RTI-76.

H L Kimmel1, F I Carroll, M J Kuhar.   

Abstract

Intracerebroventricular injections of the irreversible dopamine transporter (DAT) inhibitor, RTI-76 [3beta-(3-p-chlorophenyl) tropan-2beta-carboxylic acid p-isothiocyanatophenylethyl ester hydrochloride], decreased DAT binding in both the striatum and nucleus accumbens as measured by both [3H]GBR12935 and by [3H]WIN35,428. This decrease was dose-related, with 100 nmol RTI-76 producing approximately a 50% decrease in both regions. The maximal inhibition of DAT binding was observed 24 h after RTI-76 injection, and binding was fully restored 7 days after injection. The DAT protein half-life determined under these conditions was about 2 days. [3H]Nisoxetine binding at norepinephrine transporters in the cortex was not altered by RTI-76 administration at any time point or dose examined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728879     DOI: 10.1016/s0028-3908(99)00160-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

1.  Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum.

Authors:  Michele Zoli; Milena Moretti; Alessio Zanardi; J Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 2.  Model systems for analysis of dopamine transporter function and regulation.

Authors:  Moriah J Hovde; Garret H Larson; Roxanne A Vaughan; James D Foster
Journal:  Neurochem Int       Date:  2018-09-01       Impact factor: 3.921

3.  Simultaneous measurement of extracellular dopamine and dopamine transporter occupancy by cocaine analogs in squirrel monkeys.

Authors:  Heather L Kimmel; Jonathon A Nye; Ronald Voll; Jiyoung Mun; Jeffrey Stehouwer; Mark M Goodman; John R Votaw; F I Carroll; Leonard L Howell
Journal:  Synapse       Date:  2012-03-16       Impact factor: 2.562

4.  Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference.

Authors:  Deepak R Thakker; Francois Natt; Dieter Hüsken; Rainer Maier; Matthias Müller; Herman van der Putten; Daniel Hoyer; John F Cryan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

5.  Daily monitoring of dopamine efflux reveals a short-lasting occlusion of the dopamine agonist properties of d-amphetamine by dopamine transporter blockers GBR 12909 and methylphenidate.

Authors:  Soyon Ahn; Anthony G Phillips
Journal:  ACS Chem Neurosci       Date:  2013-05-03       Impact factor: 4.418

6.  Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine Release.

Authors:  Elena H Chartoff; Shayla R Ebner; Angela Sparrow; David Potter; Phillip M Baker; Michael E Ragozzino; Mitchell F Roitman
Journal:  Neuropsychopharmacology       Date:  2015-08-04       Impact factor: 7.853

7.  Low or high cocaine responding rats differ in striatal extracellular dopamine levels and dopamine transporter number.

Authors:  Anna M Nelson; Gaynor A Larson; Nancy R Zahniser
Journal:  J Pharmacol Exp Ther       Date:  2009-09-03       Impact factor: 4.030

8.  Brain Region-Specific Trafficking of the Dopamine Transporter.

Authors:  Ethan R Block; Jacob Nuttle; Judith Joyce Balcita-Pedicino; John Caltagarone; Simon C Watkins; Susan R Sesack; Alexander Sorkin
Journal:  J Neurosci       Date:  2015-09-16       Impact factor: 6.167

9.  Epigenetic Regulation of the Ontogenic Expression of the Dopamine Transporter.

Authors:  Ashley L Green; Aseel Eid; Le Zhan; Helmut Zarbl; Grace L Guo; Jason R Richardson
Journal:  Front Genet       Date:  2019-11-04       Impact factor: 4.599

10.  DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics.

Authors:  Darko Turic; James Swanson; Edmund Sonuga-Barke
Journal:  Pharmgenomics Pers Med       Date:  2010-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.